Cellbxhealth Plc · LSE:CLBX
Cellbxhealth — ANGLE — EACR / Illumina webinar (February 2025)
21 slides from Cellbxhealth's conference presentation, Feb 6, 2025
Slide 1: Exploring the dual analysis of circulating tumour cells and circulating tumour DNA
Exploring the dual analysis of circulating tumour cells and circulating tumour DNA Anne-Sophie Pailhes-Jimenez Senior Director, R&D ANGLE Europe Ltd EACR / Illumina webinar © ANGLE plc 2025 06 February 2025
Slide 2: Disclaimer
Disclaimer I am an employee from ANGLE Europe Limited. The opinions expressed during this presentation are my own and ANGLE’s and may not represent the opinions of Illumina. Any uses of ANGLE and Illumina products described in this presentation may be uses that have not been cleared or approved by t
Slide 3: The potential of liquid biopsy throughout the patient care pathway
The potential of liquid biopsy throughout the patient care pathway © ANGLE plc 2025 3
Slide 4: Liquid Biopsy and CTCs
Liquid Biopsy and CTCs Blood as liquid Biopsy: ➢ Minimally-invasive ➢ Repeatable ➢ Representative of cancer heterogeneity ➢ Versatile ➢ Informative Klaus Pantel and Catherine Alix-Panabieres. Liquid biopsy and minimal residual disease — latest advances and implications for cure. Nat Rev Clin Oncol 1
Slide 5: CTCs and ctDNA provide complementary information
CTCs and ctDNA provide complementary information Hypothesis: Dual analysis provides critical information not otherwise available on cancer Retrospective Active cancer Prospective progression and for targeted treatment selection ctDNA ctDNA and ctc-DNA ctc-DNA Patient immune system Active disease bei
Slide 6: Circulating tumour cells (CTCs)
Circulating tumour cells (CTCs) CTC and CTC clusters: • Reflective of metastatic tumor • Source of biomarkers (suitable for multiomics analysis) • Rare event: 1 CTC / 109 blood cells Importance of upstream workflow to generate quality sample. © ANGLE plc 2025 6
Slide 7: Parsortix PC1 system
Parsortix® PC1 system The first FDA cleared / CE-IVD medical device for the capture and harvest of circulating tumor cells from metastatic breast cancer patient blood for user-validated subsequent analysis. Intended use “The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich c
Slide 8: Parsortix systems: capturing and harvesting living cancer cells
Parsortix systems: capturing and harvesting living cancer cells Plan view Platform technology The Parsortix system harvests cancer cells from blood based on their larger size and lack of deformability Other cells can be captured: Inlet Outlet • white blood cells associated with the tumor microenviro
Slide 9: Workflow
Workflow 9
Slide 10: Workflow allowing for CTCs and ctDNA analysis
Workflow allowing for CTCs and ctDNA analysis Dual analysis of biomarkers present in plasma and cellular component Proof Of Concept work: No CTC loss following plasma removal, prior to Parsortix enrichment. https://uscnorriscancer.usc.edu/liquid-biopsy-research-core/ https://angleplc.com/wp-content/
Slide 11: Molecular analysis of CTCs and ctDNA
Molecular analysis of CTCs and ctDNA ctDNA and Parsortix-derived CTC-DNA can be analysed from single blood sample across multiple cancer types to detect mutations using Illumina Cell-Free DNA prep with enrichment combined with custom panel targeting Lung Cancer. Blood separation DNA extraction Libra
Slide 12: DNA dual analysis Assay performance (1/2)
DNA dual analysis Assay performance (1/2) Study design for evaluation of performance of DNA dual analysis Contrived samples were used to assess the analytical performance of the assay: ➢ Two cell lines with known mutations, were spiked into Parsortix-enriched samples ➢ DNA samples from CTC were extr
Slide 13: DNA dual analysis Assay performance (1/2)
DNA dual analysis Assay performance (1/2) 2.0 BRAFp.V600E 0.8 CDK4p.R24C 1.0 PIK3CAp.G118D 2.0 PTENp.T167A BRAFp.V600E CDK4p.R24C PIK3CAp.G118D PTEN 0.8 1.5 0.6 1.5 0.6 %VAF %VAF %VAF %VAF 1.0 0.4 1.0 0.4 0.5 0.2 0.5 0.2 0.0 0.0 0.0 0.0 d ls ls ls ls lls 10 s ed 20 s lls lls 10 s lls 10 s ed ed 20 s
Slide 14: DNA dual analysis of Patients with Lung cancer
DNA dual analysis of Patients with Lung cancer Patient data 1/4 2 cohorts of Lung Cancer patient - 1st cohort: 8 Lung Cancer patient samples (no treatment) - 2nd cohort: 19 Lung Cancer patient samples (may be under treatment) ✓ Good quality samples ✓ Overall, 93% of samples with at least one oncogen
Slide 15: DNA dual analysis of Patients with Lung cancer
DNA dual analysis of Patients with Lung cancer Patient data 2/4 1st cohort - Lung cancer panel (n=8): CTC(average)= 49 and CTC(median)= 20 100% patients showed oncogenic mutations signal for one or more targets. 32 genes (74 variants) seem to be specifically detected in this cohort: Table: example o
Slide 16: Dual analysis of Patients with Lung cancer
Dual analysis of Patients with Lung cancer Patient data 3/4 2nd cohort - Lung cancer panel (n=19): CTC(average)= 4 and CTC(median)= 3 90% of patients with at least one oncogenic mutations in CTC for one or more targets. 38 genes (214 variants) have been specifically detected in this cohort: Table: e
Slide 17: DNA dual analysis of Patients with Lung cancer
DNA dual analysis of Patients with Lung cancer Patient data 4/4 Full cohort - Lung cancer panel (n=27): 43 genes (247 variants) have been specifically detected in this cohort: Analysing both analytes give access to twice as many mutations, which could be investigated and/or use as “potential” biomar
Slide 18: DNA dual analysis of Patients with Lung cancer
DNA dual analysis of Patients with Lung cancer Validation of data using another technology Validation of patient data using another cohort of patient samples (under treatment – n=10) Use of a pan-CANCER NGS panel, with blocker displacement amplification 20 genes (27 variants) have been specifically
Slide 19: Conclusions
Conclusions 19
Slide 20: Parsortix DNA dual analysis strategy: Conclusion
Parsortix DNA dual analysis strategy CONCLUSION ✓ Successful detection of potential actionable targets in cfDNA and CTC, from the same sample. ✓ CTC samples provide a unique detection of actionable targets in most of the patient samples. ✓ This study highlights the potential for multiomic analysis.
Slide 21: Thank you for your attention!
Thank you for your attention! ANGLE plc 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom www.angleplc.com Anne-Sophie PAILHES-JIMENEZ a.pailhes-jimenez@angleplc.com